P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE... by Prithviraj Bose, Sanjay Mohan, Stephen Oh, Jason Gotlib, Ellen Ritchie, Taizo Shimomura, Haris Ali, Francoise Boyer, Paola Guglielmelli, Anthony M. Hunter, Betty Lamothe, Yi Cui, Francis Seguy, Amanda Mcbride, Francesca Palandri, Masahiro Takeuchi, Jean-Jacques Kiladjian

Get full text

Identification and Reproducibility of Plasma Metabolomic Biomarkers of Habitual Food Intake in a US Diet Validation Study by Ying Wang, Rebecca A. Hodge, Victoria L. Stevens, Terryl J. Hartman, Marjorie L. McCullough

Get full text

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY by A. Suvannasankha, N. Bahlis, S. Trudel, K. Weisel, C. Koenecke, A. Oriol, P. M. Voorhees, A. A. Alonso, N. S. Callander, M. V. Mateos Manteca, N. Reddy, S. Hakim, N. Patel, D. Williams, R. C. Jewell, X. Zhou, I. Gupta, A. K. Nooka

Get full text

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON by L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, P. Moreau

Get full text

P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY by Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia

Get full text

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP... by M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, A. Krishnan

Get full text

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM... by Salomon Manier, Alexander Lesokhin, Mohamad Mohty, Ruben Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah M. Larson, Asya Nina Varshavsky-Yanovsky, Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J Bahlis, Carlos Fernandez de Larrea, Noopur Raje, Eric Leip, Sharon T. Sullivan, Mohamed Elmeliegy, Andrea Viqueira, Ajay Nooka

Get full text

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations by Crimp C, Gangal A, Tarabadkar ES, Shinohara MM

“…Caitlin Crimp,1 Ameya Gangal,2 Erica S Tarabadkar,3 Michi M Shinohara1,4 1Division of Dermatology, University of Washington, Seattle, WA, USA; 2School of Medicine, Emory University, Atlanta, GA, USA; 3Department of Dermatology, Emory University School of Medicine; Winship Cancer Institute, Atlanta, GA, USA; 4Fred Hutchinson Cancer Center, Seattle, WA, USACorrespondence: Michi M Shinohara, University of Washington, 1959 NE Pacific St., Box 356524, Seattle, WA, 98195, USA, Tel +1 206-616-8523, Fax +1 206-598-4768, Email mshinoha@uw.eduAbstract: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL) and often has an indolent course, particularly for patients presenting with early-stage (patch/plaque) disease. …”
Get full text

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... by S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia

Get full text

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... by P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt

Get full text

Long non-coding RNA in glioma: novel genetic players in temozolomide resistance by Jungwook Roh, Mijung Im, JiHoon Kang, BuHyun Youn, Wanyeon Kim

Get full text

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by N. W. C. J van de Donk, R Popat, C Hulin, S Jagannath, A Oriol, P. G Richardson, T Facon, K Weisel, J. T Larsen, M Minnema, A Abdallah, A. Z Badros, S Knop, E. A Stadtmauer, M Chen, T. V Nguyen, A Amin, T Peluso, S Lonial

Get full text

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer by Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam

Get full text

Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual by Jon A. Hoin, Bradley C. Carthon, Shantoria J. Brown, Lynn M. Durham, L. Crain Garrot, Sharad A. Ghamande, Andrew W. Pippas, Brian M. Rivers, Cindy T. Snyder, Sheryl Gordon Ann Gabram-Mendola, Sheryl Gordon Ann Gabram-Mendola

Get full text

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 T... by Nizar J Bahlis, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z Orlowski, Kihyun Kim, Maria-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Ignacio Casas-Avilés, Alessia Spirli, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Paul Richardson

Get full text

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer by Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele

Get full text

icuARM-An ICU Clinical Decision Support System Using Association Rule Mining by Chih-Wen Cheng, Nikhil Chanani, Janani Venugopalan, Kevin Maher, May Dongmei Wang

Get full text

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer by Jun A, Baotong Zhang, Zhiqian Zhang, Hailiang Hu, Jin-Tang Dong

Get full text

The Involvement of Long Non-Coding RNAs in Glutamine-Metabolic Reprogramming and Therapeutic Resistance in Cancer by Jungwook Roh, Mijung Im, Yeonsoo Chae, JiHoon Kang, Wanyeon Kim

Get full text

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models by Chrystal Paulos, Gregory B Lesinski, Zachary S Buchwald, Nabil F Saba, Vikash Kansal, Andre J Burnham, Brendan L C Kinney, Nicole C Schmitt

Get full text